Addex Therapeutics (ADXN) Competitors $8.02 -0.07 (-0.80%) Closing price 08/22/2025 03:43 PM EasternExtended Trading$8.02 0.00 (0.00%) As of 08/22/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADXN vs. KPTI, ALXO, CALC, AKTX, TPST, EQ, CLNN, NCNA, ESLA, and MRSNShould you be buying Addex Therapeutics stock or one of its competitors? The main competitors of Addex Therapeutics include Karyopharm Therapeutics (KPTI), ALX Oncology (ALXO), CalciMedica (CALC), Akari Therapeutics (AKTX), Tempest Therapeutics (TPST), Equillium (EQ), Clene (CLNN), NuCana (NCNA), Estrella Immunopharma (ESLA), and Mersana Therapeutics (MRSN). These companies are all part of the "pharmaceutical products" industry. Addex Therapeutics vs. Its Competitors Karyopharm Therapeutics ALX Oncology CalciMedica Akari Therapeutics Tempest Therapeutics Equillium Clene NuCana Estrella Immunopharma Mersana Therapeutics Karyopharm Therapeutics (NASDAQ:KPTI) and Addex Therapeutics (NASDAQ:ADXN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership. Which has more risk & volatility, KPTI or ADXN? Karyopharm Therapeutics has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500. Comparatively, Addex Therapeutics has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500. Do analysts rate KPTI or ADXN? Karyopharm Therapeutics presently has a consensus price target of $34.00, suggesting a potential upside of 439.68%. Addex Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 273.83%. Given Karyopharm Therapeutics' higher probable upside, research analysts clearly believe Karyopharm Therapeutics is more favorable than Addex Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Karyopharm Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Addex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger valuation and earnings, KPTI or ADXN? Addex Therapeutics has lower revenue, but higher earnings than Karyopharm Therapeutics. Addex Therapeutics is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKaryopharm Therapeutics$145.24M0.38-$76.42M-$14.59-0.43Addex Therapeutics$170.62K49.86$8.02M-$0.34-23.60 Does the media refer more to KPTI or ADXN? In the previous week, Karyopharm Therapeutics had 2 more articles in the media than Addex Therapeutics. MarketBeat recorded 2 mentions for Karyopharm Therapeutics and 0 mentions for Addex Therapeutics. Karyopharm Therapeutics' average media sentiment score of 0.62 beat Addex Therapeutics' score of 0.00 indicating that Karyopharm Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Karyopharm Therapeutics Positive Addex Therapeutics Neutral Is KPTI or ADXN more profitable? Addex Therapeutics has a net margin of 3,584.49% compared to Karyopharm Therapeutics' net margin of -90.02%. Karyopharm Therapeutics' return on equity of 0.00% beat Addex Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Karyopharm Therapeutics-90.02% N/A -84.28% Addex Therapeutics 3,584.49%-54.27%-49.15% Do institutionals & insiders have more ownership in KPTI or ADXN? 66.4% of Karyopharm Therapeutics shares are held by institutional investors. Comparatively, 16.1% of Addex Therapeutics shares are held by institutional investors. 3.0% of Karyopharm Therapeutics shares are held by insiders. Comparatively, 15.0% of Addex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryKaryopharm Therapeutics and Addex Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Addex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADXN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADXN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADXN vs. The Competition Export to ExcelMetricAddex TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.25M$2.54B$5.75B$9.62BDividend YieldN/A1.57%4.40%4.10%P/E Ratio-23.6022.9131.3026.05Price / Sales49.86554.08432.98193.75Price / CashN/A180.4637.7358.48Price / Book0.775.939.536.61Net Income$8.02M$31.83M$3.26B$265.65M7 Day Performance1.07%1.89%2.13%2.02%1 Month Performance-4.12%1.33%2.80%-0.31%1 Year Performance4.90%8.84%30.68%19.06% Addex Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADXNAddex Therapeutics2.318 of 5 stars$8.03-0.8%$30.00+273.8%+1.6%$9.25M$170.62K-23.6030KPTIKaryopharm Therapeutics3.8173 of 5 stars$3.83+1.6%$34.00+787.5%-46.6%$33.13M$145.24M-0.29380ALXOALX Oncology3.2006 of 5 stars$0.62+0.7%$3.30+433.1%-49.8%$33.06MN/A-0.2540Analyst RevisionCALCCalciMedica3.3138 of 5 stars$2.36-14.7%$16.00+579.4%-33.5%$33.04MN/A-1.5230Gap DownAKTXAkari Therapeutics2.3551 of 5 stars$1.03-2.4%$5.00+387.8%-75.1%$32.98MN/A0.009TPSTTempest Therapeutics1.1849 of 5 stars$8.50+6.1%$30.00+252.9%-47.2%$31.23MN/A-0.4720EQEquillium0.9439 of 5 stars$0.87-1.7%$3.00+244.4%+102.2%$31.22M$41.10M-2.2440Gap DownHigh Trading VolumeCLNNClene3.2406 of 5 stars$3.77-1.3%$40.00+961.0%+6.8%$31.18M$340K-0.93100Analyst ForecastNCNANuCana3.4273 of 5 stars$5.00+11.9%$5,000.00+99,900.0%-99.8%$31.04MN/A-0.7330Earnings ReportGap DownESLAEstrella Immunopharma2.2714 of 5 stars$0.85-1.7%$16.00+1,782.4%-26.5%$30.74MN/A-3.27N/AMRSNMersana Therapeutics4.2244 of 5 stars$6.08+1.8%$130.00+2,038.2%-78.0%$30.34M$40.50M-0.41150 Related Companies and Tools Related Companies Karyopharm Therapeutics Alternatives ALX Oncology Alternatives CalciMedica Alternatives Akari Therapeutics Alternatives Tempest Therapeutics Alternatives Equillium Alternatives Clene Alternatives NuCana Alternatives Estrella Immunopharma Alternatives Mersana Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADXN) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Addex Therapeutics Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Addex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access